Replies to post #21893 on Rich Pharmaceuticals Inc. (fka RCHA)

[beer$$money]

Agreed and IMO that news is coming concerning the HypGen Deal? I'm curious as to how this article missed the fact that this purchase of shares was an Insider??


What positive implications?

The accredited investor is a lone investor and he/she has purchased 333,333,333 shares of company common stock at $.0003 per share, and warrants to purchase the same number of common shares at the same price per share for a five-year term.

That’s a substantial purchase, even if it’s at a discount to current open market pricing. This, in turn, further reinforces our expectations that we are about to get some big news from the company. Not from a capital perspective, as was the case with the latest SEC filing, but from an operational standpoint.

In all likelihood (and as per the most reasonable assumption) this development should relate to the HypGen deal and the collaboration asset. For anyone that missed the update back in July, the collaboration is set up to bring an asset to market that’s targeting Parkinson’s disease. If successful, the company is looking at a billion-dollar market.

https://insiderfinancial.com/rich-pharmaceuticals-inc-otcmktsrcha-ran-as-expected-heres-whats-next

Item 3.02 Unregistered Sales of Equity Securities



On October 16, 2017, Rich Pharmaceuticals, Inc. (the “Company”) executed a subscription agreement and warrant with Richard L. Chang, LLC Holdings (the “Investor”) pursuant to which the Investor purchased 333,333,333 shares of Company common stock at $.0003 per share, and warrants to purchase 333,333,333 shares of Company common stock at $.0003 per share for a five-year term. The sale of the shares and warrants was made in reliance on the exemption provided by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) for the offer and sale of securities not involving a public offering. The Company's reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by the Company which did not involve a public offering; (b) there was only a one investor who was an accredited investor; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; and (e) the issuance of shares was pursuant to subscription agreement and warrant negotiated directly between the Investor and the Company

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12333247

I'm taking a closer look at HypGen & the RCHA relationship with them:)

Mega Bridge, Inc. To Be Known as Hypgen Inc. Consulting ...

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12326744


HYPGEN INC.

(FORMERLY MEGA BRIDGE INC.)

NOTES TO CONDENSED FINANCIAL STATEMENTS

AUGUST 31, 2017


NOTE 9: RELATED PARTY TRANSACTIONS


The director of the Company made the initial $100 deposit to on the bank account. In September 2015 the director paid audit fees on behalf of the company in the amount of $650. These amounts, totaling $750, are being carried as a Related Party Loan which bears no interest and is payable on demand. The related party loan was forgiven effective January 18, 2017 under terms of change in control (SEE NOTE 1).



On January 27, 2017, the Company entered into a one year convertible note from a related party with the face value of $100,000 bearing 8% interest (SEE NOTE 3).



On June 28, 2017, Richard L. Chang was appointed as a director of the Company. Mr. Richard Chang is the controlling interest in Richard Chang Holdings, LLC.



On June 28, 2017, Ben Chang, a senior management consultant, loaned the Company, $100 to initially fund the operating bank account of the Company. Mr. Ben Chang is also the Chief Executive Officer of Rich Pharmaceuticals, Inc.



On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited (“Apica”). Apica is controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy. Pursuant to that agreement the Company agreed issued 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 6), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

Tin Chew

https://www.linkedin.com/in/tin-chew-9a13364/



Mr. Chew Chuan Tin
Co-Trainer – Millionaire Investor Program

Professional investor and a successful entrepreneur
Ex-fund manager with over US$2 billion under management
Consistently generated over 21% annual return on investment

http://ads1.shareinvestor.com/email/20090522_marketrally/

Singaporean Chew Chuan Tin remembers the first dotcom bubble very well. He had just graduated at the top of his class at National University of Singapore with a first-class honors degree in business administration, majoring in finance. After receiving multiple scholarships, he chose to do his graduate programme at University of California, Berkeley, in 1995. That was when he saw some of his classmates become millionaires overnight just on the strength of their ideas. “

That was the start of the internet boom and a great time to be an entrepreneur,” he recounts.

After completing his graduate studies, Chew became a venture capitalist at Vertex Venture Holdings, a member of Temasek Holdings. He was based in Silicon Valley and invested in software companies and start-ups. “California is a real melting pot — no matter what your background is, if you work hard and have the talent, you can make it in life,” says Chew.

https://sg.finance.yahoo.com/news/property-hunters-020000123.html



On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. (“Raferty”). Raferty is controlled by Antonio Treminio, former CEO of the Company. Pursuant to this agreement the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 6), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.


Rafferty Finance S.A.
Antonio Treminio

Chairman of Immunovative Inc and Chief Executive Officer of Immunovative Inc, Immunovative Therapies Ltd.


Mr. Antonio Treminio serves as Interim President at Luna Technologies International, Inc. Mr. Treminio serves as Chairman and Chief Executive Officer of Immunovative Inc. He served as Chief Executive Officer at Mega Bridge Inc. from January 18, 2017 to June 28, 2017. Mr. Treminio served as Special Advisor of Strategic Planning at NQ Minerals PLC until February 16, 2017. He served as Interim Chief Executive Officer and Vice President of Operations at Luna Technologies International, Inc. since February 7, 2007 and July 01, 2006 respectively. He served as President of Tauriga Sciences, Inc. from October 06, 2008 to May 2009, Chief Executive Officer since October 06, 2008 and Chief Financial Officer since October 06, 2008. He also served as Chairman, Acting Principal Accounting Officer, Treasurer and Secretary of Tauriga Sciences, Inc. He was a Co-Founder of ROI Land Investments Ltd and served as its Vice President of Strategic Planning until March 13, 2016. Mr. Treminio served as the Chief Executive Officer and President of Blackbird Petroleum Corporation (now Blackbird International Corporation) from September 15, 2008 to September 26, 2010. Mr. Treminio served as the Chief Financial Officer and Principal Accounting Officer of Blackbird Petroleum until September 26, 2010. He officially launched his professional career with Dean Witter Reynolds, having completed the renowned Dean Witter Stockbroker training program in 1994 in New York city. Mr. Treminio also worked at PaineWebber and since then he has been successful investment banker, entrepreneur and has been able successful fund, grow and up-list several of his previous companies to higher quoted markets such as NASDAQ, AMEX AND/OR NYSE MKT. He has over 20 years of experience in the financial markets with special focus on corporate financing for private and public companies. Over the years Mr. Treminio has assisted a number of different public companies meet and/or secured their capital requirements. He served as key investor and has provided bridge financing to many of his previous clients. Mr. Treminio manages all matters relating to public listing requirements, corporate finance, marketing and public relations. He has a unique blend of technological skill, human relations and business expertise. His specific set of skills are to provide businesses with effective strategies on corporate structuring and/or packaging, negotiations, gathering market intelligence with the objective to secure working capital for growth, expansion, as well as for mergers and acquisitions. He served as Chief Executive Officer and President of Nouveau Holdings, Ltd. from September 18, 2007 to January 30, 2008. He served as Chief Executive Officer and President of Startcall.com Inc. Mr. Treminio served as Director of Corporate Development of Comstock Mining, Inc. since March 2003. In this role, Mr. Treminio guided and oversaw all aspects of corporate development, branding, investor and shareholder relations for GoldSpring. Mr. Treminio served as the President and Chief Executive Officer of Goldspring Inc. since December 2002 and also served as its Interim President since January 2003 and its Interim President until March 2003. He served as Chairman and Director of Ark Development, Inc. (now Blackbird International Corporation) from September 15, 2008 to September 26, 2010. He serves as a Director of Novo Energies International, Ltd. He served as Director and Member of Advisory Board at ROI Land Investments Ltd until August 12, 2015. He served as a Director at Mega Bridge Inc. from January 18, 2017 to June 28, 2017. He served as a Member of Business Advisory Board and Director at Tauriga Sciences, Inc. since October 06, 2008 and October 06, 2008 respectively. He served as a Director of Comstock Mining, Inc. (also known as Goldspring Inc). He was educated in Canada and moved to the United States in 1993 to establish business agreements with Latin American financial institutions. From 1989 to 1993, he attended studies in Business Administration at Loyalist College in Belleville, Ontario.

https://www.bloomberg.com/research/stocks/private/person.asp?personId=4907008&privcapId=10361313



On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC (“Imagic”). Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. Upon the commencement of this engagement, the consultant or it’s designees were issued shares of the Company in the amount of 12,000,000 common shares. Imagic was also issued a warrant to acquire 10,000,000 shares of the Company at an exercise price of $0.25. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 6), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12326744

[SkyTrader7]

They get ready for much more ...

[stockmaster007]

Part of reason I am also buying. Little downside and huge upside